PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 1515511
PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 1515511
Biopharma Buffer Market was valued at USD 4,899.23 Million in 2023, expanding at a CAGR of 11.5% from 2024 to 2032.
Biopharma Buffers are solutions that maintain a stable pH level and are crucial in various stages of biopharmaceutical production, such as cell culture, purification, formulation isolation, polishing, filtration, chromatographic reaction, and crystallization. These buffers ensure that the biochemical reactions in biopharmaceutical processes run efficiently and yield high-quality products.
Biopharma Buffer Market- Market Dynamics
Increasing research and development activities are driving growth.
With the sector rapidly expanding, there is a substantial reliance on biological buffers throughout the research, development, and production phases. The increasing use of cell culture techniques in developing drugs, making vaccines, and advancing regenerative medicine shows how important biological buffers are. These buffers help maintain the right pH levels, crucial for keeping cellular processes working effectively. Because of this, the need for top-notch buffers is growing as the biopharmaceutical field expands.
The biopharmaceutical buffer market is experiencing significant momentum, driven by strategic alliances. A recent partnership between Asahi Kasei Bioprocess America and GeminiBio focused on accelerating the adoption of inline buffer formulation technology to optimize biopharmaceutical manufacturing processes.
Biopharma Buffer Market- Key Insights
As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 11.5% over the forecast period (2024-2032)
Based on Type segmentation, Pre-Formulated Buffers were predicted to show maximum market share in the year 2023
Based on Application segmentation, Cell Culture was the leading type in 2023
Based on Component segmentation, Amino Acids was the leading type in 2023
Based on Buffer Preparation, Liquid was the leading type in 2023
Based on Material Form, Liquid was the leading type in 2023
Based on End User segmentation, Pharmaceutical Companies were the leading type in 2023
Based on region, North America was the leading revenue generator in 2023
The Global Biopharma Buffer Market is segmented based on Type, Application, Component, Buffer Preparation, Material Form, End User, and Region.
The market is divided into three categories based on Type: Pre-formulated Buffers, Customized Buffers, Concentrated Buffers, and Others. Pre-formulated buffers are likely strong contenders due to their convenience and cost-effectiveness for routine applications. They're readily available off-the-shelf, saving time and resources for researchers and manufacturers.
The market is divided into four categories based on End Users: Pharmaceutical companies, Academic institutions, Hospitals, and Others. Biopharma buffers play a critical role throughout the biopharmaceutical manufacturing process, optimizing efficiency and product quality. By strategically selecting buffers at each stage, pharmaceutical companies ensure a robust and cost-effective manufacturing process, ultimately delivering high-quality drugs to patients.
Biopharma Buffer Market- Geographical Insights
The North American region is expected to see substantial growth in demand for the biopharma buffer market. This surge is driven by their proven effectiveness and innovative applications, which are gaining popularity among clients. The market share for biopharmaceutical buffers is expected to rise significantly in North America, fueled by increasing rates of chronic diseases among the ageing population and the demographic shift towards more elderly individuals. Recently, many pharmaceutical companies have begun developing highly innovative products, further enhancing this trend.
The Biopharma Buffer market is experiencing steady growth driven by factors like rising demand for biopharmaceuticals and increased R&D activity. Some of the dominant players in the industry are Merck KGaA, Thermo Fisher Scientific, and Sigma-Aldrich. These companies leverage their strong presence in the broader chemical market and extensive distribution networks. They offer a wide range of pre-formulated and concentrated buffers, catering to various biopharmaceutical applications. Further, the biopharma buffer market is witnessing the emergence of novel buffer technologies, such as continuous buffer exchange and in-line buffer conditioning.
In December 2023, South Korea's Hanwha Group will re-enter the biopharmaceutical market to become the country's sole producer of tris buffers, a key reagent used for medical experiments such as generic DNA tests.
In Jan 2022, Aceto, a global provider of specialty materials for life sciences and advanced technology end markets, consolidated and integrated its six manufacturing-related acquisitions to achieve a hybrid manufacturing/distribution model providing key benefits to its customers in high-growth end markets including pharmaceuticals, biopharmaceuticals, vaccines, nutraceuticals, agriculture, cosmetics and specialty chemicals.
GLOBAL BIOPHARMA BUFFER MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS
Merck KGaA
Thermo Fisher Scientific Inc.
Avantor, Inc.
Lonza Group Ltd.
Bio-Rad Laboratories, Inc.
Sartorius AG
Corning Inc.
Becton, Dickinson and Company (BD)
GE Healthcare
Promega Corporation
Cardinal Health
Techcon Systems
Masterflex
Charles River Laboratories
Thorlabs
Others